113.17
+3.83%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Par Drugs and Chemicals
Its shares trade on NSE under the ticker PAR.NS. It has been listed since 16 May 2019. In the fiscal year to 31 March 2026, it reported revenue of ₹1.04bn and net income of ₹131.1m. At that date it held total assets of ₹1.29bn and shareholders' equity of ₹1.12bn.
Par Drugs & Chemicals Ltd. engages in the development and manufacture of Active Pharma Ingredients (API) for the domestic market as well as for exports to international markets. The company is headquartered in Bhavnagar, Gujarat. The company went IPO on 2019-05-16. The firm also produces a range of antacid molecules. The Company’s products include magnesium hydroxide, magnesium trisilicate, magnesium carbonate, light magnesium oxide, magnesium oxide heavy, magnesium oxide USP, dried aluminum hydroxide gel, magaldrate, magnesium aluminum silicate hydrated, alma gate, hydrotalcite, aluminum hydroxide magnesium carbonate co-dried gel, aluminum-magnesium silicate BP, sodium aluminum silicate, precipitated silica, magnesium silicate, amorphous, colloidal silicon dioxide and sucralfate USP. The firm owns and operates its manufacturing facilities at Bhavnagar in Gujarat. The company has over four manufacturing blocks at Bhavnagar, which are for different products having a capacity of approximately 9,700 metric tons per annum.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 16 May 2019
- Website
- pardrugs.com ↗
Leadership
Pay as last reported
- Mr. Falgun SavaniChairman of the Board, Managing Director, Promoter₹4.3m
- Mr. Jignesh SavaniChief Executive Officer, Executive Director, Promoter₹4.3m
- Mr. Chintan ChauhanChief Financial Officer₹420,003
- Mr. Sanket TrivediCompliance Officer, Company Secretary₹320,182
- Mr. Ghanshayambhai SavaniWhole Time Director, since 2012₹4.3m
- Ms. Naynaben SavaniNon-Executive Director₹9,000
- Ms. Shilpa SavaniNon-Executive Director₹5,000
- Mrs. Bintal ShahIndependent Director
- Mr. Pravin BhayaniNon-Executive Independent Director₹9,000
- Ms. Krishna ShahNon-Executive Independent Director₹8,000
- Ms. Kajal VaghaniNon-Executive Independent Director₹5,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Par Drugs & Chemicals Ltd. manufactures 9,700 metric tons of API annually in Bhavnagar.
- The company produces magnesium hydroxide and aluminum hydroxide for global markets.
- Par Drugs & Chemicals Ltd. has four manufacturing blocks for diverse pharmaceutical products.
Weaknesses
- The firm focuses solely on Bhavnagar for all manufacturing operations.
- Par Drugs & Chemicals Ltd. lacks international manufacturing facilities outside India.
- The company's product range is limited to antacid molecules and API.
Opportunities
- Par Drugs & Chemicals Ltd. can expand API exports to new international markets.
- The company may increase production capacity beyond 9,700 metric tons annually.
- Par Drugs & Chemicals Ltd. can develop new antacid molecules for emerging markets.
Threats
- The pharmaceutical industry faces strict regulatory changes in India and globally.
- Par Drugs & Chemicals Ltd. depends on Bhavnagar for all manufacturing operations.
- The company's reliance on antacid molecules makes it vulnerable to market shifts.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.